Results 251 to 260 of about 213,320 (307)

The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson's Disease Experiencing End-of-Dose Motor Fluctuations. [PDF]

Parkinsons Dis
Harrison-Jones G, Green W, Bainbridge J.
europepmc   +1 more source

Correction: Health technology assessment of surgical robots: a mini-review of a rapidly evolving field. [PDF]

Front Public Health
Zhang T, Zhong Y, Zeng J, Liu GG.
europepmc   +1 more source

Patents, Innovation and Access to New Pharmaceuticals [PDF]

Henry Grabowski
core  

Some of the next articles are maybe not open access.

Related searches:

Economics of the Pharmaceutical Industry

Journal of Economic Literature, 2018
The pharmaceutical industry accounts for a substantial chunk of the US economy's research and development investments, which have resulted in significant medical breakthroughs. At the same time, the costs of pharmaceutical products continue to rise, as does pressure to adopt direct or indirect controls on pharmaceutical prices.
Darius N Lakdawalla
exaly   +2 more sources

New economics of the pharmaceutical supply chain

American Journal of Health-System Pharmacy, 2005
During the last 10 years, the landscape of the pharmaceutical supply chain has changed tremendously and evolved into a mature and thriving industry. The transformation is essentially complete, with over 100 distributors narrowed down to three national, professionally managed public companies ...
exaly   +3 more sources

Pharmaceutical Economics

2013
William S. Comanor, Stuart O. Schweitzer
exaly   +2 more sources

Economic Evaluation of Pharmaceuticals

PharmacoEconomics, 1992
The increased pressures on health care budgets have emphasised the need to demonstrate the value for money from health technologies. Most major pharmaceutical companies have therefore commissioned cost-benefit or cost-effectiveness analysis of their products. There is an assumed analogy between clinical trains, which are required for product licensing,
openaire   +4 more sources

Economic Evaluation of Pharmaceuticals

PharmacoEconomics, 1993
In recent years there has been a large increase in the number of economic evaluations of pharmaceuticals. Many of these studies have been commissioned by individual pharmaceutical companies, in support of new or existing products. In 2 countries, Australia and Canada (in the province of Ontario), draft guidelines issued by the government have ...
Michael Drummond, Frans Rutten, Antonio Brenna, Carlos Gouveia Pinto, Bruno Horisberger, Bengt Jönsson, Claude Le Pen, Joan Rovira, Matthias Graf von der Schulenburg, Harri Sintonen, Koen Torfs   +10 more
openaire   +2 more sources

The Ethics and Economics of Pharmaceutical Pricing

Annual Review of Pharmacology and Toxicology, 2015
The cost of drugs is a major and rapidly rising component of health-care expenditures. We survey recent literature on the ethics and economics of skyrocketing pharmaceutical prices and find that advances in economic research have increased the sharpness and focus of the ethically based calls to increase access by modifying patent protection and ...
Sara, Parker-Lue, Michael, Santoro, Greg, Koski   +2 more
openaire   +2 more sources

The Economics of Pharmaceutical Policy in Ghana

International Journal of Health Services, 1980
Pharmaceutical expenditure in Ghana accounts for about one-third of the total recurrent costs of the Ministry of Health, but in isolation this figure is a misleading indicator of economic importance. In the primary care sector up to 75–80 percent of the running cost of a health center may be accounted for by pharmaceuticals, and because the Ghanaian ...
A, Barnett, A L, Creese, E C, Ayivor
openaire   +2 more sources